Since CGRP Antibodies cannot be found in anyone’s formulary yet, we’ll have to abide by the time honored trigger avoidance strategies during this holiday season. Most agree the holiday season is meant to be a exceptionally joyful time of year. But a migraine can ruin the fun and celebration, and suck out the “joy” for sure. Following are tips on
I am going to assume that most of you taking the time to read this newsletter are aware of the four big Pharma companies competing to be the first to offer a drug that may lessen, or even prevent, migraines for the more than 36 million Americans affected by this debilitating neurological illness. A quick review: Alder Biopharmaceuticals, Eli Lilly, Amgen,
The subject of this month’s newsletter began with a conversation between myself and a Human Resources Specialist around coping with an employee’s pneumonia, her chronic absences, and whether or not to place her on Intermittent FMLA. During this conversation the HR Specialist likened someone with migraine, having to take large amounts of time off, to our present case of extraordinary
Genetic investigations continue to make news in the world of migraine research. As you may recall, last year (2016) our newsletter reported a number of major genetic advances. In probably one of the best known to date, originally published in Nature Genetics, an international group of researchers isolated 38 genetic variants implicated in migraine, 28 of them previously unknown. This
First, heartfelt congratulations to everyone who participated in the wealth of activities celebrating Migraine and Headache Awareness Month 2017 (MHAM) Thanks to all who worked on and participated in the Shades of Migraine and World Migraine Solidarity Day campaign. If you did not hear about this effort, initiated by the Association of Migraine Disorders, visit www.ShadesForMigraine.org to learn about it. The campaign was
This February will witness the eleventh anniversary of “Headache on the Hill” (HOH), the highly acclaimed annual advocacy event, sponsored by the Alliance for Headache Disorders Advocacy (AHDA), designed to draw attention to the need for increased funding for research into migraine disease, pain and other headache disorders. In 2017, AHDA advocated to include NIH pain research as a component
With all of the anticipation of CGRP blockers, the sober news is that they will not be a savior for all migraine sufferers. First, like all pharmaceutical agents, they will not work for all migraine sufferers. Secondly, CGRP blockers are expensive (the current guess is that they will cost roughly $1000 a month). That is a big bill for insurance
The holiday season is already hard upon us. For some it is a time for celebration-parties, eating and drinking, enjoying time with family, and all too often, stress, a recognized migraine trigger. Remember, there exists both good stress and bad stress, but in the end it is all stress. For the migraineur this stress can be a prescription for a
It seems nowadays there is a computer app to accommodate nearly every need. The migraine world is no exception. In reviewing the various migraine app products two major and separate classes emerge. The first includes those applications allowing a migraineur to both record and interpret critical data. This data could include dietary information, sleep patterns, medications, stress levels, date/time and more.
“Merriam-Webster” definition of disability: “a physical, mental, cognitive, or developmental condition that impairs, interferes with, or limits a person’s ability to engage in certain tasks or actions or participate in typical daily activities and interactions” Controversy surrounds the question of whether or not migraine disease, in any or all of its manifestations, rises to the level of a disability.